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Comparative Frequency of Fragile-X (FMR1) and
Creatine Transporter (SLC6A8) Mutations in X-Linked
Mental Retardation
To the Editor:
The study by Rosenberg et al. (2004), in the July 2004
issue of The American Journal of Human Genetics, and
the previous work by Dr. Salomons’s laboratory on the
implications of the creatine transporter gene, SLC6A8,
for X-linked mental retardation (XLMR) are very im-
portant contributions to the ﬁeld (Salomons et al. 2001;
Rosenberg et al. 2004). I wish, however, to qualify the
concluding sentences in the abstract and the discussion
section of the study by Rosenberg et al. (2004), which
may lead readers to overestimate the incidence of muta-
tions in the creatine transporter gene inmental retardation
(MR). The authors write in the abstract that the “fre-
quency of SLC6A8 mutations in XLMR is close to that
of CGG expansions in FMR1” (Rosenberg et al. 2004,
p. 97). This is certainly incorrect. Rosenberg et al. (2004)
found a 2.2% prevalence of SLC6A8 mutations in fam-
ilies with proven or possible XLMR (the latter are families
with at least two males affected by MR and compatible
with X-linked inheritance). On the other hand, the FMR1
expansion mutation associated with fragile-X syndrome
is found in ∼2%–3% of males with MR who were not
selected for family history (these ﬁgures are based on co-
horts with little clinical preselection apart from the ex-
clusion of clearly chromosomal or syndromic forms of
MR) (see de Vries et al. 1997; Hecimovic et al. 2002;
Pandey et al. 2002; Grønskov et al. 2004; Biancalana et
al., in press). In fact, when selection is based on possible
X-linked inheritance, the proportion of individuals with
fragile-X syndrome is much higher. For instance, in the
study by Fishburn et al. (1983), fragile-X syndrome ac-
counted for MR in 12 of 45 male sib pairs with “non-
speciﬁc” MR, a proportion (27%) that is thus 110 times
higher than the reported incidence of SLC6A8 mutations
in a cohort containing sib pairs such as these as well as
families with even more obvious XLMR. In fact, we have
proposed recently that, unless there are clear hotspots of
mutations and/or a very large mutation target size (such
as for Duchenne muscular dystrophy, Rett syndrome, and
hemophilia A), the population incidence of X-linked dis-
eases implicating genes of average size that lead to highly
decreased reproductive ﬁtness is 10–20 times lower than
the incidence of fragile-X syndrome (1/50,000–1/100,000
for most X-linked diseases, compared with 1/∼5,000
males for the fragile-X syndrome) (Chelly and Mandel
2001). Thus, one expects that the contribution to XLMR
of an average gene that does not present mutation hot-
spots would be 10–20 times lower than that of FMR1.
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SLC6A8 is such a gene (with 13 exons, a 635-aa coding
sequence, and no indication of highly recurring muta-
tions), and thus we predict that its incidence in “nonsyn-
dromic” MR will be in the range of 0.1%–0.3%. Indeed,
even for the ARX (X-linked Aristaless) gene, which has
a clear mutation hotspot that accounts for ∼6.6% of fam-
ilies with X-linked “nonsyndromic” MR, the incidence of
this ARX recurring mutation in cohorts of patients with
MR is much lower (∼0.15%) than that of FMR1 muta-
tions (Grønskov et al. 2004; Mandel and Chelly 2004).
I also suggest that, in reporting prevalence estimates
that are based on relatively small numbers of positive
cases, it would be useful to give conﬁdence intervals
(CIs). Thus, the observed prevalence, in the study by
Rosenberg et al. (2004), of 2.2% may indeed be an un-
derestimate, since some mutations may have beenmissed
and some variants of uncertain signiﬁcance at present
may prove pathogenic, or it may be an overestimate of
the true prevalence, since, for the reported data, the CI
for the prevalence of proven mutations is 1.0%–4.4%.
J. L. MANDEL
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Reply to Mandel
To the Editor:
On behalf of all the authors of our recent study (Rosen-
berg et al. 2004), we thank Dr. Mandel for his comments
(Mandel 2004 [in this issue]), to which we fully subscribe,
and we apologize for the misleading statement in our
article. Indeed, SLC6A8 mutations, although probably
more common than mutations in other known nonsyn-
dromic X-linked mental retardation (MRX) genes except
ARX, must be much less frequent than pathogenic CGG
expansions in the FMR1 gene. As pointed out by Mandel
(2004 [in this issue]), this is convincingly illustrated by
the relative paucity of ARX mutations in nonselected co-
horts of males with mental retardation (MR) (Grønskov
et al. 2004). Mandel’s second argument, which implies
that mutation rates in X-linked genes can be inferred from
their lengths and must be intrinsically much lower than
the rate of CGG expansions in FMR1, is less compelling
in view of the evidence for mutational hotspots in many
disease genes, including ARX and PQBP1, a recent ad-
dition to the growing list of genes involved in MRX (Kal-
scheuer et al. 2003). Therefore, the existence of another
common but hitherto-unknown cause of nonsyndromic
MR cannot be ruled out yet, even though ongoing large-
scale mutation screening in regions known to carry many
